Paf-acether (paf) is a naturally occurring phospholipid involved in inflammatory processes. The presence of paf, its precursor lyso paf, and lipo-paf has been determined in blood and synovial fluid from 13 patients with rheumatoid arthritis (RA), 11 with spondylarthropathies, eight with other inflammatory rheumatisms, 13 with chondrocalcinosis, 15 with osteoarthritis, and also in blood from nine healthy subjects. Paf and lipo-paf were measured by rabbit platelet aggregation after isolation by high performance liquid chromatography, whereas lyso pafwas first chemically acetylated to give paf. Lipo-paf in blood was higher in patients than in controls; lipo-paf concentrations in blood and in synovial fluid were significantly higher in rheumatoid arthritis than in osteoarthritis and chondrocalcinosis. By contrast, paf and lyso paf reached their lower values in rheumatoid arthritis. The amounts of lipid mediators were not correlated with biological parameters of inflammation. Lipo-paf, which is considered as a storage form of paf, may be the important form ofpafin active inflammatory rheumatism.
Paf-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) (paf) is a phospholipid mediator implicated in various inflammatory diseases. In humans it may be involved in the pathogenesis of asthma,' chronic obstructive pulmonary diseases, and ulcerative colitis. 2 The discovery of paf in 19723 and the elucidation of its structure4 5 was an important addition to the knowledge of prostaglandins and leukotrienes. Several enzymatic steps are involved in the formation of paf, which occurs by cell stimulation. The initial substrate, a membrane phospholipid ether analogue of phosphatidylcholine, is hydrolysed by a phospholipase A2 to form l-alkyl-2-lysoglycero-phosphocholine (lyso paf-acether). The latter can in turn be acetylated by an acetyltransferase to give paf. Thus activation of phospholipase A2 leads to the release of both the precursor of paf and arachidonic acid.
Paf has been obtained in humans from platelets, blood monocytes, neutrophils, and endothelial cells.' Several pathobiological effects of paf have now been recognised. Paf is the most potent platelet aggregating agent described so far.6 It is also a neutrophil activating factor, causing chemotaxis and the release of lysosomal enzymes and free radicals. These results show that lipo-paf, which could represent a storage form of paf, is increased in the blood and synovial fluid of patients with inflammatory rheumatic diseases, especially those with rheumatoid arthritis, in agreement with the systemic nature of these diseases. Its value as a putative pathogenic index of chronic joint inflammation, either by itself or by interaction with cytokines, remains to be evaluated. With the ongoing development of paf inhibitors, it is useful to know that paf can be detected in patients with inflammatory rheumatic diseases.
